For the nine months ended the third quarter of the fiscal year ending December 2026, consolidated revenue was 1,068,074 million yen (YoY +17.2%), operating profit was 522,570 million yen (+21.6%), and net income was 375,302 million yen (+22.8%), all showing expansion. Full-year forecasts are maintained assuming revenue of 1,345,000 million yen, operating profit of 670,000 million yen on a Core basis, and a dividend of 66 yen. On a Core basis, revenue remains strong, supported by contributions from key products and new launches. Financial health metrics such as ROE and NOA remain solid. An earnings presentation will be held.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4519-20261027-01.pdf","jir_short_summary":"For the nine months ended the third quarter of the fiscal year ending December 2026, consolidated revenue was 1,068,074 million yen (YoY +17.2%), operating profit was 522,570 million yen (+21.6%), and net income was 375,302 million yen (+22.8%), all showing expansion. Full-year forecasts are maintained assuming revenue of 1,345,000 million yen, operating profit of 670,000 million yen on a Core basis, and a dividend of 66 yen. On a Core basis, revenue remains strong, supported by contributions from key products and new launches. Financial health metrics such as ROE and NOA remain solid. An earnings presentation will be held.","jir_summary":"### Overview of Results\nChugai Pharmaceutical reported revenue of 1,068,074 million yen for the third quarter of the fiscal year ending December 2026, marking a substantial increase year-over-year. Solid growth in sales of pharmaceutical products, together with contributions from overseas sales, drove the top-line increase. Core-based profit indicators also showed significant improvement. The IFRS results include effects such as amortization of intangible assets, but overall profitability improved. Supplementary materials and an IR briefing will be held online.\n\n### Outlook and Capital Allocation\nFull-year forecasts are maintained at revenue of 1,345,000 million yen, Core-based operating income of 670,000 million yen, and a dividend of 66 yen. Growth of existing products and market penetration of new products are expected to continue, and the company intends to continue development investment while maintaining shareholder returns. Results through Q3 2026 support the achievement of the full-year forecasts, and financial soundness remains at a high level.","jir_financial_highlights":"Revenue: 1,068,074 million yen (Year-over-Year +17.2%)\nOperating Income: 522,570 million yen (Year-over-Year +21.6%)\nQuarterly Net Income: 375,302 million yen (Year-over-Year +22.8%)\nDividend Forecast \/ Year-end Dividend: 66 yen (Dividend forecast for fiscal 2026)\nConsolidated Net Assets: 2,088,536 million yen (Compared to prior period +?)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #Earnings, #IFRS, #DrugDiscovery, #ROETrend","jir_key_figures":"Revenue: 1,068,074 million yen (Year-over-Year +17.2%)\nOperating Income: 522,570 million yen (Year-over-Year +21.6%)\nQuarterly Net Income: 375,302 million yen (Year-over-Year +22.8%)","jir_meta_title":"Chugai Pharmaceutical Co., Ltd. Q3 FY2026 Financial Summary | Revenue and Profits Exceed Prior Year","jir_meta_description":"Summary of Chugai Pharmaceutical's Q3 FY2026 financial results: revenue +17.2% YoY, operating income +21.6%, quarterly net income +22.8%. Full-year forecasts and dividend policy maintained. Online earnings presentation scheduled.","jir_og_title":"Chugai Pharmaceutical Q3 Results: Significant Increase in Revenue and Profit","jir_og_description":"Chugai Pharmaceutical's Q3 FY2026 results: revenue exceeded 1 trillion yen and profits rose substantially. Full-year forecasts maintained; earnings presentation to be held online.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ended December 2025\\\",\\\"September 30, 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[911640,1068074]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ended December 2025\\\",\\\"September 30, 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[429827,522570]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"September 30, 2025\\\",\\\"September 30, 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Net Income\\\",\\\"data\\\":[305602,375302]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"domestic_product_sales_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Domestic Product Sales Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Oncology\\\",\\\"Specialty\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Domestic Product Sales\\\",\\\"data\\\":[4063,2995]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"overseas_sales_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Overseas Product Sales Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Americas\\\",\\\"Asia\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Overseas Product Sales\\\",\\\"data\\\":[5004,0,0]}]},\\\"options\\\":{}}\"}]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-134984","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n